Don quixote and the quest for personalized medicine

Journal of Clinical Oncology

Volumn 26, Issue 16, 2008, Pages 2619-2620

  Allegra, Carmen J ^a   Benedetti, Jacqueline K ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA TOPOISOMERASE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADD ON THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL MEDICINE; COLORECTAL CANCER; DNA FRAGMENTATION; EDITORIAL; IMMUNOHISTOCHEMISTRY; MEDICAL DECISION MAKING; POPULATION; PRIORITY JOURNAL; PROGNOSIS; SAMPLE; SAMPLE SIZE; CLASSIFICATION; COLORECTAL TUMOR; GENETICS; HUMAN; ISOLATION AND PURIFICATION; NOTE; PREDICTION AND FORECASTING; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 45749156881     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.8922     Document Type: Editorial

References (9)

1. Lockhart DJ, Winzeler FA: Genomics, gene expression and DNA arrays. Nature 405:827-836, 2000
2. Taube SE, Jacobson JW, Lively TG: Cancer diagnostics: Decision criteria for marker utilization in the clinic. Am J Pharmacogenomics 5:357-364, 2005
3. Amado RG, Wolf M, Freeman D, et al: Panitumumab (pmab) efficacy and patient-reported outcomes (PRO) in metastatic colorectal cancer (mCRC) patients (pts) with wild-type (WT) KRAS tumor status. Proc Am Soc Clin Oncol GI Cancer Symposium; (abstr 278), 2008
4. Braun MS, Richman SD, Quirke P, et al: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from a large randomized trial. J Clin Oncol 26:2690-2698, 2008
5. Seymour MT, Maughan TS, Ledermann JA, et al: For the FOCUS Trial Investigators and the National Cancer Res Institute Colorectal Clinical Studies Group: Different strategies of sequential and combination chemotherapy for patients with poor-prognosis advanced colorectal cancer - A randomized controlled trial. Lancet 370:143-152, 2007
6. Tsao YP, Russo A, Nyamuswa G, et al: Interaction between replication forks and topoisomerase 1-DNA cleavage complexes: Studies in a cell-free SV-40 DNA replication system. Cancer Res 53:5908, 1993
7. Pommier V, Pourquier P, Urasaki Y, et al: Topoisomerase 1 inhibitors: Selectivity and cellular resistance. Drug Resistance Update 2:307-318, 1999
8. Woessner RD, Eng WK, Hofmann GZ, et al: Camptothecin hyperresistant P388 cells: Drug-dependent reduction in topoisomerase 1 content. Oncol Res 4:481, 1992
9. Koopman M, Antonini NF, Douma J, et al: Sequential verses combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomized controlled trial. Lancet 370:135-142, 2007